Skip to content 
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | 27.41M | 51.17M | [{"date":"2024-12-31","value":53.57,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 70.24M | 77.24M | [{"date":"2024-12-31","value":90.94,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (42.83M) | (26.07M) | [{"date":"2024-12-31","value":-4282900000,"profit":false},{"date":"2025-12-31","value":-2607000000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 5.27M | 2.46M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":46.7,"profit":true}] | |||
| Pre-Tax Income | (37.56M) | (23.61M) | [{"date":"2024-12-31","value":-3756100000,"profit":false},{"date":"2025-12-31","value":-2361000000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (47.79M) | (21.81M) | [{"date":"2024-12-31","value":-4778600000,"profit":false},{"date":"2025-12-31","value":-2180800000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (47.79M) | (21.81M) | [{"date":"2024-12-31","value":-4778600000,"profit":false},{"date":"2025-12-31","value":-2180800000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
| SCTX | |
|---|---|
| Current Ratio | 0.66 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| SCTX | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| SCTX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 3.43 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.43 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| SCTX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 11.60 |
| P/B | 0.00 |
| Price/FCF | NM |
| EV/R | 8.59 |
| EV/Ebitda | NM |
Scribe Therapeutics Inc. Common Stock (SCTX) share price today is $26
Yes, Indians can buy shares of Scribe Therapeutics Inc. Common Stock (SCTX) on Vested. To buy
Yes, you can purchase fractional shares of Scribe Therapeutics Inc. Common Stock (SCTX) via the Vested app. You can start investing in Scribe Therapeutics Inc. Common Stock (SCTX) with a minimum investment of $1.
You can invest in shares of Scribe Therapeutics Inc. Common Stock (SCTX) via Vested in three simple steps:
The 52-week high price of Scribe Therapeutics Inc. Common Stock (SCTX) is $26.21. The 52-week low price of Scribe Therapeutics Inc. Common Stock (SCTX) is $15.
The price-to-earnings (P/E) ratio of Scribe Therapeutics Inc. Common Stock (SCTX) is
The price-to-book (P/B) ratio of Scribe Therapeutics Inc. Common Stock (SCTX) is 0.00
The dividend yield of Scribe Therapeutics Inc. Common Stock (SCTX) is 0.00%
The market capitalization of Scribe Therapeutics Inc. Common Stock (SCTX) is $479.34M
The stock symbol (or ticker) of Scribe Therapeutics Inc. Common Stock is SCTX
Consider the share price of Scribe Therapeutics Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Scribe Therapeutics Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Scribe Therapeutics Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Scribe Therapeutics Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Scribe Therapeutics Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Scribe Therapeutics Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
